Author : adminDate : 2022-10-14 09:18

HLB completes preparatory meeting with FDA for approval of liver cancer drug

Local biotech company HLB is stepping up efforts to win a novel drug approval in the United States for its liver cancer treatment Rivoceranib, after completing a pre-new drug application (NDA) meeting with the U.S. Food and Drug Administration (FDA), the company said Wednesday. 

Please refer to the following website for further details: